RU2004114239A - Производные пиримидина - Google Patents
Производные пиримидина Download PDFInfo
- Publication number
- RU2004114239A RU2004114239A RU2004114239/04A RU2004114239A RU2004114239A RU 2004114239 A RU2004114239 A RU 2004114239A RU 2004114239/04 A RU2004114239/04 A RU 2004114239/04A RU 2004114239 A RU2004114239 A RU 2004114239A RU 2004114239 A RU2004114239 A RU 2004114239A
- Authority
- RU
- Russia
- Prior art keywords
- solvates
- accordance
- stereoisomers
- compounds
- pharmaceutically acceptable
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 3
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 20
- 125000004432 carbon atom Chemical group C* 0.000 claims 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 7
- -1 COOA Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 4
- 238000002316 cosmetic surgery Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000023819 chronic asthma Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 201000005857 malignant hypertension Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 230000002572 peristaltic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000017443 reproductive system disease Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- NQNKTEPVLXMIMZ-UHFFFAOYSA-N 1-[[4-[(3-chloro-4-methoxyphenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]methyl]piperidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CN2CCC(CC2)C(O)=O)=NC2=C1C(CCCC1)=C1O2 NQNKTEPVLXMIMZ-UHFFFAOYSA-N 0.000 claims 1
- NNWUSHVWRVXPDE-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(NCC=2C=C3OCOC3=CC=2)=C(C2=C(CCCC2)O2)C2=N1 NNWUSHVWRVXPDE-UHFFFAOYSA-N 0.000 claims 1
- CZCHFJKMIBUBEA-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]butanoic acid Chemical compound C1CCCC2=C1C1=C(NCC=3C=C4OCOC4=CC=3)N=C(CCCC(=O)O)N=C1O2 CZCHFJKMIBUBEA-UHFFFAOYSA-N 0.000 claims 1
- HUAVDXDNTYXBHM-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=C4OCOC4=CC=3)N=C(C=3C=CC(=CC=3)C(O)=O)N=C2N1C(C)C1=CC=CC=C1 HUAVDXDNTYXBHM-UHFFFAOYSA-N 0.000 claims 1
- QSNFUGKZIPUHDA-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=C4OCOC4=CC=3)N=C(CCCC(O)=O)N=C2N1C(C)C1=CC=CC=C1 QSNFUGKZIPUHDA-UHFFFAOYSA-N 0.000 claims 1
- GVCKTMDSNYLKIX-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-9-ethylpyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound N1=C2N(CC)C3=CC=CC=C3C2=C(NCC=2C=C3OCOC3=CC=2)N=C1C1=CC=C(C(O)=O)C=C1 GVCKTMDSNYLKIX-UHFFFAOYSA-N 0.000 claims 1
- ZEGVBBAQLJNQIC-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-ylmethylamino)-9-methylpyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound N1=C2N(C)C3=CC=CC=C3C2=C(NCC=2C=C3OCOC3=CC=2)N=C1C1=CC=C(C(O)=O)C=C1 ZEGVBBAQLJNQIC-UHFFFAOYSA-N 0.000 claims 1
- RHGZPXUZNLWBFN-UHFFFAOYSA-N 4-[4-(benzylamino)-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(NCC=2C=CC=CC=2)=C(C2=C(CCCC2)O2)C2=N1 RHGZPXUZNLWBFN-UHFFFAOYSA-N 0.000 claims 1
- HJQVHXMFGPYYMB-UHFFFAOYSA-N 4-[4-(benzylamino)-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=CC=CC=3)N=C(C=3C=CC(=CC=3)C(O)=O)N=C2N1C(C)C1=CC=CC=C1 HJQVHXMFGPYYMB-UHFFFAOYSA-N 0.000 claims 1
- DJKBNLVPBWGBBA-UHFFFAOYSA-N 4-[4-(benzylamino)-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=CC=CC=3)N=C(CCCC(O)=O)N=C2N1C(C)C1=CC=CC=C1 DJKBNLVPBWGBBA-UHFFFAOYSA-N 0.000 claims 1
- UZAQIDLEQNBHRW-UHFFFAOYSA-N 4-[4-(pyridin-3-ylmethylamino)-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(NCC=2C=NC=CC=2)=C(C2=C(CCCC2)O2)C2=N1 UZAQIDLEQNBHRW-UHFFFAOYSA-N 0.000 claims 1
- OSJWLATVPVOJAO-UHFFFAOYSA-N 4-[4-[(3,4-dichlorophenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC(NCC=2C=C(Cl)C(Cl)=CC=2)=C(C2=C(CCCC2)O2)C2=N1 OSJWLATVPVOJAO-UHFFFAOYSA-N 0.000 claims 1
- MNVURNPCAFUWAS-UHFFFAOYSA-N 4-[4-[(3,4-dichlorophenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=C(Cl)C(Cl)=CC=3)N=C(C=3C=CC(=CC=3)C(O)=O)N=C2N1C(C)C1=CC=CC=C1 MNVURNPCAFUWAS-UHFFFAOYSA-N 0.000 claims 1
- ZEAGRMPBDYPIOU-UHFFFAOYSA-N 4-[4-[(3,4-dichlorophenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=2CCCCC=2C2=C(NCC=3C=C(Cl)C(Cl)=CC=3)N=C(CCCC(O)=O)N=C2N1C(C)C1=CC=CC=C1 ZEAGRMPBDYPIOU-UHFFFAOYSA-N 0.000 claims 1
- AUBBHTUIGOZGMA-UHFFFAOYSA-N 4-[4-[(3,4-dimethoxyphenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C(CCCC1)=C1O2 AUBBHTUIGOZGMA-UHFFFAOYSA-N 0.000 claims 1
- LKISWYYAEJUCEA-UHFFFAOYSA-N 4-[4-[(3,4-dimethoxyphenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C(CCCC1)=C1N2C(C)C1=CC=CC=C1 LKISWYYAEJUCEA-UHFFFAOYSA-N 0.000 claims 1
- MESTYQKDMOEGCZ-UHFFFAOYSA-N 4-[4-[(3,4-dimethoxyphenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC(CCCC(O)=O)=NC2=C1C(CCCC1)=C1N2C(C)C1=CC=CC=C1 MESTYQKDMOEGCZ-UHFFFAOYSA-N 0.000 claims 1
- QPNZIXBAGHSUDN-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C(CCCC1)=C1O2 QPNZIXBAGHSUDN-UHFFFAOYSA-N 0.000 claims 1
- WCMGPGKZRVBEQR-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-2-yl]butanoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CCCC(O)=O)=NC2=C1C(CCCC1)=C1O2 WCMGPGKZRVBEQR-UHFFFAOYSA-N 0.000 claims 1
- PIGSKNWUSJGIEQ-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C(CCCC1)=C1N2C(C)C1=CC=CC=C1 PIGSKNWUSJGIEQ-UHFFFAOYSA-N 0.000 claims 1
- JLVXHUKXMIGDLP-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9-(1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CCCC(O)=O)=NC2=C1C(CCCC1)=C1N2C(C)C1=CC=CC=C1 JLVXHUKXMIGDLP-UHFFFAOYSA-N 0.000 claims 1
- LSGARYMRAHMZSS-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9-ethylpyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound N1=C(C=2C=CC(=CC=2)C(O)=O)N=C2N(CC)C3=CC=CC=C3C2=C1NCC1=CC=C(OC)C(Cl)=C1 LSGARYMRAHMZSS-UHFFFAOYSA-N 0.000 claims 1
- ICNLPHFDBDHXCX-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9-methylpyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C1=CC=CC=C1N2C ICNLPHFDBDHXCX-UHFFFAOYSA-N 0.000 claims 1
- FBNJWEYOMPECSE-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9-propan-2-ylpyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C1=CC=CC=C1N2C(C)C FBNJWEYOMPECSE-UHFFFAOYSA-N 0.000 claims 1
- SBNHMWDXHZZFMY-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9h-pyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C1=CC=CC=C1N2 SBNHMWDXHZZFMY-UHFFFAOYSA-N 0.000 claims 1
- OFLREZIRQOQCBG-UHFFFAOYSA-N 4-[4-[(3-chloro-4-methoxyphenyl)methylamino]-9h-pyrimido[4,5-b]indol-2-yl]butanoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CCCC(O)=O)=NC2=C1C1=CC=CC=C1N2 OFLREZIRQOQCBG-UHFFFAOYSA-N 0.000 claims 1
- OYESANTZCMXAPV-UHFFFAOYSA-N 4-[9-benzyl-4-[(3-chloro-4-methoxyphenyl)methylamino]pyrimido[4,5-b]indol-2-yl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(C=2C=CC(=CC=2)C(O)=O)=NC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 OYESANTZCMXAPV-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims 1
- 206010059053 Shunt stenosis Diseases 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 210000001715 carotid artery Anatomy 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- RKDIOIRJBXNUMP-UHFFFAOYSA-N n-[(3-chloro-4-methoxyphenyl)methyl]-2-(piperazin-1-ylmethyl)-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-4-amine Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CN2CCNCC2)=NC2=C1C(CCCC1)=C1O2 RKDIOIRJBXNUMP-UHFFFAOYSA-N 0.000 claims 1
- GMPSWDFCGJATKB-UHFFFAOYSA-N n-[(3-chloro-4-methoxyphenyl)methyl]-2-[(4-methylsulfonylpiperazin-1-yl)methyl]-5,6,7,8-tetrahydro-[1]benzofuro[2,3-d]pyrimidin-4-amine Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(CN2CCN(CC2)S(C)(=O)=O)=NC2=C1C(CCCC1)=C1O2 GMPSWDFCGJATKB-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10148883A DE10148883A1 (de) | 2001-10-04 | 2001-10-04 | Pyrimidinderivate |
| DE10148883.1 | 2001-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004114239A true RU2004114239A (ru) | 2005-10-27 |
Family
ID=7701322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004114239/04A RU2004114239A (ru) | 2001-10-04 | 2002-09-05 | Производные пиримидина |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7312224B2 (enExample) |
| EP (1) | EP1432715B1 (enExample) |
| JP (1) | JP4782376B2 (enExample) |
| KR (1) | KR20040041166A (enExample) |
| CN (1) | CN1863803A (enExample) |
| AT (1) | ATE389655T1 (enExample) |
| AU (1) | AU2002362806B2 (enExample) |
| BR (1) | BR0213037A (enExample) |
| CA (1) | CA2462799C (enExample) |
| DE (2) | DE10148883A1 (enExample) |
| ES (1) | ES2303564T3 (enExample) |
| HU (1) | HUP0401654A3 (enExample) |
| PL (1) | PL369819A1 (enExample) |
| RU (1) | RU2004114239A (enExample) |
| WO (1) | WO2003031447A2 (enExample) |
| ZA (1) | ZA200403334B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2454419C2 (ru) * | 2005-12-21 | 2012-06-27 | Байер Шеринг Фарма Акциенгезельшафт | Новые ациклические, замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний |
| RU2462249C2 (ru) * | 2006-08-29 | 2012-09-27 | Актелион Фармасьютиклз Лтд | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибитор pde5 |
| RU2468027C2 (ru) * | 2006-12-07 | 2012-11-27 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы фосфоинозитид-3-киназы и способы их применения |
| RU2625316C1 (ru) * | 2016-04-13 | 2017-07-13 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005061171A1 (de) | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
| DE102007027799A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
| DE102007027800A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
| DE102007051762A1 (de) * | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| DE102007054786A1 (de) * | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
| WO2011143607A1 (en) * | 2010-05-14 | 2011-11-17 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
| WO2012012712A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
| WO2013112651A2 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| EP3194399B1 (en) | 2014-09-17 | 2019-04-10 | Pécsi Tudományegyetem | New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders |
| WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
| WO2017092523A1 (zh) * | 2015-12-02 | 2017-06-08 | 深圳市塔吉瑞生物医药有限公司 | 一种稠合嘧啶化合物及包含该化合物的组合物及其用途 |
| CN105461728A (zh) * | 2015-12-29 | 2016-04-06 | 中山大学 | 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037980A (en) * | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| GB915304A (en) * | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives |
| JPS5542999B2 (enExample) * | 1972-02-14 | 1980-11-04 | ||
| CH592668A5 (enExample) | 1973-10-02 | 1977-10-31 | Delalande Sa | |
| US4487626A (en) | 1980-08-22 | 1984-12-11 | E. I. Du Pont De Nemours And Company | Herbicidal sulfonamides |
| ZA815765B (en) * | 1980-08-22 | 1983-04-27 | Du Pont | Herbicidal sulfonamides |
| JP2562520B2 (ja) * | 1989-09-19 | 1996-12-11 | 帝人株式会社 | ピロロ〔２，３ーｄ〕ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤 |
| EP0514540B1 (en) | 1989-09-19 | 1996-07-17 | Teijin Limited | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| DE19644228A1 (de) | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| DE19752952A1 (de) | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
| DE19819023A1 (de) | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| JP4611524B2 (ja) | 1998-06-02 | 2011-01-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピロロ［２，３ｄ］ピリミジン組成物およびその使用 |
| DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| DE19944604A1 (de) | 1999-09-17 | 2001-03-22 | Merck Patent Gmbh | Aminderivate |
| DK1246623T3 (da) | 1999-12-02 | 2006-11-13 | Osi Pharm Inc | Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf |
| EA007254B1 (ru) | 2000-12-01 | 2006-08-25 | Оси Фармасьютикалз, Инк. | Соединения, специфические к аденозиновому а, аи арецептору, и их применение |
-
2001
- 2001-10-04 DE DE10148883A patent/DE10148883A1/de not_active Withdrawn
-
2002
- 2002-09-04 US US10/491,680 patent/US7312224B2/en not_active Expired - Fee Related
- 2002-09-05 DE DE50211929T patent/DE50211929D1/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/EP2002/009935 patent/WO2003031447A2/de not_active Ceased
- 2002-09-05 KR KR10-2004-7003997A patent/KR20040041166A/ko not_active Withdrawn
- 2002-09-05 AT AT02800556T patent/ATE389655T1/de not_active IP Right Cessation
- 2002-09-05 HU HU0401654A patent/HUP0401654A3/hu unknown
- 2002-09-05 PL PL02369819A patent/PL369819A1/xx unknown
- 2002-09-05 CA CA2462799A patent/CA2462799C/en not_active Expired - Fee Related
- 2002-09-05 AU AU2002362806A patent/AU2002362806B2/en not_active Ceased
- 2002-09-05 EP EP02800556A patent/EP1432715B1/de not_active Expired - Lifetime
- 2002-09-05 CN CNA028195817A patent/CN1863803A/zh active Pending
- 2002-09-05 BR BR0213037-8A patent/BR0213037A/pt not_active Application Discontinuation
- 2002-09-05 RU RU2004114239/04A patent/RU2004114239A/ru not_active Application Discontinuation
- 2002-09-05 JP JP2003534430A patent/JP4782376B2/ja not_active Expired - Fee Related
- 2002-09-05 ES ES02800556T patent/ES2303564T3/es not_active Expired - Lifetime
-
2004
- 2004-05-03 ZA ZA200403334A patent/ZA200403334B/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2454419C2 (ru) * | 2005-12-21 | 2012-06-27 | Байер Шеринг Фарма Акциенгезельшафт | Новые ациклические, замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний |
| RU2462249C2 (ru) * | 2006-08-29 | 2012-09-27 | Актелион Фармасьютиклз Лтд | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибитор pde5 |
| RU2468027C2 (ru) * | 2006-12-07 | 2012-11-27 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы фосфоинозитид-3-киназы и способы их применения |
| RU2625316C1 (ru) * | 2016-04-13 | 2017-07-13 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1432715B1 (de) | 2008-03-19 |
| BR0213037A (pt) | 2004-10-05 |
| CA2462799A1 (en) | 2003-04-17 |
| JP2005504847A (ja) | 2005-02-17 |
| DE50211929D1 (en) | 2008-04-30 |
| US20040242595A1 (en) | 2004-12-02 |
| PL369819A1 (en) | 2005-05-02 |
| EP1432715A2 (de) | 2004-06-30 |
| AU2002362806B2 (en) | 2008-09-18 |
| HUP0401654A2 (hu) | 2004-11-29 |
| DE10148883A1 (de) | 2003-04-10 |
| KR20040041166A (ko) | 2004-05-14 |
| ZA200403334B (en) | 2006-05-31 |
| US7312224B2 (en) | 2007-12-25 |
| CA2462799C (en) | 2010-11-02 |
| ATE389655T1 (de) | 2008-04-15 |
| JP4782376B2 (ja) | 2011-09-28 |
| CN1863803A (zh) | 2006-11-15 |
| WO2003031447A2 (de) | 2003-04-17 |
| HUP0401654A3 (en) | 2006-02-28 |
| WO2003031447A3 (de) | 2003-08-28 |
| ES2303564T3 (es) | 2008-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004114239A (ru) | Производные пиримидина | |
| RU99110944A (ru) | Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v) | |
| AR035676A1 (es) | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| FR21C1010I2 (fr) | 2,4,di-(hetero-) arylamino (-oxy)-5 pyrimidines substitutees utilisees comme agents antineoplasiques | |
| JPH09132528A (ja) | コルチコトロピン放出因子アンタゴニストの新規使用 | |
| RU2003117478A (ru) | Применение тиенопиримидинов | |
| JP5562865B2 (ja) | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター | |
| GT200000170A (es) | Agentes terapeuticos. | |
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| AU2007228997A1 (en) | Pharmaceutical combination composition comprising at least one PKC inhibitor and at least one JAK3 kinase inhibitor for treating autoimmune disorders | |
| JP2011514363A5 (enExample) | ||
| KR20010014678A (ko) | 돌연사 방지를 위하여 ｃｒｆ 길항제를 이용한 ｑｔ 분산및 심박수 변동성의 개선 | |
| MX2007014081A (es) | Pteridinas utiles como inhibidores del virus de la hepatitis c (hcv) y metodos para la preparacion de las mismas. | |
| RU2009128966A (ru) | Новые производные аминопиримидина в качестве ингибиторов plr1 | |
| CA2429979A1 (en) | Treatment of statin side effects | |
| EP1476192B1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| GB0128499D0 (en) | Therapeutic agents | |
| RU2000116899A (ru) | Тиенопиримидины | |
| US8071596B2 (en) | Endothelin receptor antagonists | |
| US6777419B1 (en) | Pyrazolo [4,3-d]pyrimidines | |
| AU757409B2 (en) | Hiv integrase inhibitors | |
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| RU2004110042A (ru) | Тиено[2,3-d] пиримидины с комбинированной агонистической активностью lh и fsh | |
| EA200700144A1 (ru) | Производные пиридопиримидина, их получение, их применение в терапии | |
| KR20030071880A (ko) | 피라졸로[４,３-ｄ]피리미딘과 엔도델린 수용체 길항제또는 티에노피리미딘과 엔도델린 수용체 길항제를포함하여 이루어지는 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20051201 |